Treatment of spasticity with botulinum toxin

被引:55
|
作者
O'Brien, CF [1 ]
机构
[1] Elan Pharmaceut, San Diego, CA 92121 USA
来源
CLINICAL JOURNAL OF PAIN | 2002年 / 18卷 / 06期
关键词
spasticity; neural pathways; demyelination; botulinum toxin;
D O I
10.1097/00002508-200211001-00011
中图分类号
R614 [麻醉学];
学科分类号
100217 ;
摘要
Spasticity is an abnormal increase in muscle contraction often caused by damage to central motor pathways that control voluntary movement. During clinical examination, spasticity manifests as an increase in stretch reflexes, producing tendon jerks and resistance appearing as muscle tone. There are many causes of spasticity, including demyelination from multiple sclerosis, congenital damage from diseases such as cerebral palsy, trauma to the brain or spinal cord, hemorrhage or infarction, and other pathologic conditions that interrupt neural pathways. Effects of spasticity range from mild muscle stiffness to severe, painful muscle contractures and repetitive spasms that reduce mobility and substantially impede normal activitics of daily living. Botulinum toxin therapy reduces spasticity and pain associated with several disorders. Local treatment with botulinum toxins can be used as adjunctive therapy, along with oral antispasticity medications, or alone to provide localized decrease in symptoms of spasticity and pain. Botulinum toxin therapy may be particularly useful for patients with spasticity due to stroke, whose treatment can be tailored based on recovery of function over time. In addition, botulinum toxin therapy is safe for pediatric patients, including children with cerebral palsy, who may not be able to tolerate the cognitive side effects of oral medications. Results of studies evaluating botulinum toxin for the treatment of spasticity due to various causes are presented here.
引用
收藏
页码:S182 / S190
页数:9
相关论文
共 50 条
  • [21] Physiological effects of botulinum toxin in spasticity
    Gracies, JM
    MOVEMENT DISORDERS, 2004, 19 : S120 - S128
  • [22] Botulinum toxin in the management of spasticity in children
    Benrhouma, H.
    Yacoubi, J.
    Kraoua, I.
    Klaa, H.
    Ben Youssef-Turki, I.
    Gouider-Khouja, N.
    REVUE NEUROLOGIQUE, 2014, 170 (8-9) : 541 - 547
  • [23] Experience of botulinum toxin in the management of spasticity
    Barnes, MP
    EUROPEAN JOURNAL OF NEUROLOGY, 1997, 4 : S33 - S35
  • [24] Therapy with botulinum toxin in patients with spasticity
    Messner, M.
    Ceballos-Baumann, A.
    NERVENHEILKUNDE, 2008, 27 (12) : 1109 - +
  • [25] Botulinum toxin for the treatment of spasticity in children: attainment of treatment goals
    Weigl, Daniel M.
    Arbel, Nili
    Katz, Kalman
    Becker, Tali
    Bar-On, Elhanan
    JOURNAL OF PEDIATRIC ORTHOPAEDICS-PART B, 2007, 16 (04): : 293 - 296
  • [26] Botulinum toxin treatment in upper limb spasticity: Treatment consistency
    Papavasiliou, Antigone S.
    Nikaina, Irene
    Bouros, Panagiotis
    Rizou, Ioanna
    Filiopoulos, Constantine
    EUROPEAN JOURNAL OF PAEDIATRIC NEUROLOGY, 2012, 16 (03) : 237 - 242
  • [27] Disability changes after treatment of upper limb spasticity with botulinum toxin
    Reiter, F
    Danni, M
    Ceravolo, MG
    Provinciali, L
    JOURNAL OF NEUROLOGIC REHABILITATION, 1996, 10 (01): : 47 - 52
  • [28] BOTULINUM TOXIN TREATMENT OF SPASTICITY-RELATED PAIN: A CASE REPORT
    Fonseca, Joao P.
    Branquinho, Lurdes
    Malta, Joao
    Veiros, Iolanda
    Amaral, Carla
    TOXICON, 2021, 190 : S25 - S26
  • [29] Overview of botulinum toxin as a treatment for spasticity in stroke patients
    Hirotaka Isoyama
    Naoyuki Takeuchi
    World Journal of Neurology, 2013, 3 (04) : 133 - 137
  • [30] Botulinum toxin treatment of lumbrical spasticity - A brief report
    Palmer, DT
    Horn, LJ
    Harmon, RL
    AMERICAN JOURNAL OF PHYSICAL MEDICINE & REHABILITATION, 1998, 77 (04) : 348 - 350